Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes

[Image: see text] Acetyl-CoA carboxylase (ACC) inhibitors offer significant potential for the treatment of type 2 diabetes mellitus (T2DM), hepatic steatosis, and cancer. However, the identification of tool compounds suitable to test the hypothesis in human trials has been challenging. An advanced s...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffith, David A., Kung, Daniel W., Esler, William P., Amor, Paul A., Bagley, Scott W., Beysen, Carine, Carvajal-Gonzalez, Santos, Doran, Shawn D., Limberakis, Chris, Mathiowetz, Alan M., McPherson, Kirk, Price, David A., Ravussin, Eric, Sonnenberg, Gabriele E., Southers, James A., Sweet, Laurel J., Turner, Scott M., Vajdos, Felix F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281100/
https://www.ncbi.nlm.nih.gov/pubmed/25423286
http://dx.doi.org/10.1021/jm5016022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281100/
https://www.ncbi.nlm.nih.gov/pubmed/25423286
http://dx.doi.org/10.1021/jm5016022

Ejemplares similares